Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide-based novel combination study in relapsed or refractory multiple myeloma
2023-509384-25-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Dec 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of mezigdomide, tazemetostat, trametinib and dexamethasone in multiple myeloma (MM) (3 arms), sponsored by Celgene Corporation. Primary endpoints: Safety and Recommended Phase 2 Dose. Planned start Dec 2022; status: authorised.
02
Drugs
mezigdomidetazemetostattrametinibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-509384-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509384-25-00.